UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1361-6
Program Prior Authorization/Notification
Medication Empaveli® (pegcetacoplan)
P&T Approval Date 7/2021, 7/2022, 8/2023, 2/2024, 4/2024, 4/2025
Effective Date 7/1/2025
1. Background:
Empaveli (pegcetacoplan) is a complement inhibitor indicated for the treatment of adult
patients with paroxysmal nocturnal hemoglobinuria (PNH).1
2. Coverage Criteriaa:
A. Initial Authorization
1. Empaveli will be approved based on all of the following criteria:
a. Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH)
-AND-
b. One of the following:
(1) Patient will not be prescribed Empaveli in combination with another
complement inhibitor used for the treatment of PNH (e.g., Bkemv, Fabhalta,
PiaSky, Soliris, Ultomiris)
-OR-
(2) Patient is currently receiving another complement inhibitor (e.g., Bkemv,
Fabhalta, PiaSky, Soliris, Ultomiris) which will be discontinued and Empaveli
will be initiated in accordance with the United States Food and Drug
Administration approved labeling
Authorization will be issued for 12 months.
B. Reauthorization
1. Empaveli will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Empaveli therapy
-AND-
b. Patient is not receiving Empaveli in combination with another complement inhibitor
used for the treatment of PNH (e.g., Bkemv, Fabhalta, PiaSky, Soliris, Ultomiris )
© 2025 UnitedHealthcare Services Inc.
1
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may also be in place.
4. References:
1. Empaveli [package insert], Waltham, MA: Apellis Pharmaceuticals, Inc.; February 2024.
Program Prior Authorization/Notification - Empaveli® (pegcetacoplan)
Change Control
7/2021 New program
7/2022 Annual review. Added state mandate with no other changes to coverage
criteria.
8/2023 Annual review. Updated reference.
2/2024 Added Fabhalta to list of examples of other complement inhibitors used
for the treatment of PNH. Revised initial authorization to 12 months.
Included criteria for therapeutic duplication. Updated references.
4/2024 Simplified criteria language for converting to new complement inhibitor
therapy.
4/2025 Annual review. No changes to coverage criteria. Updated examples of
alternate complement inhibitors.
© 2025 UnitedHealthcare Services Inc.
2